Author

Stefan Rutkowski

University Medical Center Hamburg-EppendorfORCID 0000-0002-5446-9571Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:differential expression· 2 Organism:human· 2 Approach:statistical model· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:clustering· 1 Approach:deep learning· 1 Assay:scATAC-seq· 1

Frequent Co-Authors

Stefan Michael PfisteriD· 2 shared Andrea Wittmann· 1 shared Andrey KorshunoviD· 1 shared Anne RademacheriD· 1 shared Arzu Onar-Thomas· 1 shared Ashley MargoliD· 1 shared Banlanjo Abdulaziz UmaruiD· 1 shared Barbara JonesiD· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Stefan Michael PfisterORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologybioRxivPreprintMay 6, 2026

hTERT Expression, Regulation, and Prognostic Significance in Pediatric Medulloblastoma

Ryuma Tanaka, Banlanjo Abdulaziz Umaru, Matthew Sobo…·Rachid Drissi

This study examines hTERT expression and its prognostic impact in pediatric medulloblastoma, finding higher expression correlates with worse survival outcomes.

DOI 10.64898/2026.05.01.722294

humanbulk RNA-seq

𝕏 PostBluesky

Cancer BiologyNaturePeer-reviewedMay 7, 2025

Medulloblastoma oncogene aberrations are not involved in tumor initiation, but essential for disease progression and therapy resistance

Konstantin Okonechnikov, Piyush K. Joshi, Verena Körber…·Stefan Michael Pfister

The paper uses single-cell technologies to show that large-scale chromosomal aberrations drive medulloblastoma initiation, while single-gene oncogenic events like MYC contribute to progression and therapy resistance.

27 citationstop 1%

humanscRNA-seq

𝕏 PostBluesky